View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
A calcium channel blocker, clevidipine butyrate (Cleviprex) is the first new I.V. drug approved for hypertension in 10 years. This novel antihypertensive drug is effective for treating severe acute hypertension in the ED and for managing BP in perioperative settings. Compared with similar drugs, clevidipine has the advantage of a short half-life (less than 1 minute), so it can be titrated quickly and precisely.
Unlike many other I.V. antihypertensives on the market, clevidipine is metabolized in the blood and tissues, not the kidneys or liver, so it doesn't accumulate in the body. This may be a significant advantage for critically ill patients with renal or hepatic dysfunction.
For more information, visit http://www.cleviprex.com.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top